Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02460731 · ClinicalTrials.gov registry record · Phase 1

Young Plasma Transfusions for Progressive Supranuclear Palsy

A Phase 1 study of Progressive Supranuclear Palsy, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target
1
Study location

NCT02460731 is a Phase 1 study of Progressive Supranuclear Palsy that has completed, run by University of California, San Francisco. The registered enrollment target is 6 participants, below the 452-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02460731, a Phase 1 study of Progressive Supranuclear Palsy, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

This is a phase 1, multi-center, open-label study of the safety, tolerability, pharmacodynamics, and preliminary efficacy of young (\<30 years of age) healthy male donor plasma transfusions in patients with PSP. Up to 10 subjects will receive once monthly 4-unit transfusions of young healthy male donor plasma for 6 months.

Interventions

  • BIOLOGICAL Fresh Frozen Plasma

Study Locations (1)

California

  • University of California, San Francisco, Memory and Aging Center - San Francisco

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2015-05
Est. Completion 2019-12
Phase Phase 1

What the Registry Record Tells You About NCT02460731

The ClinicalTrials.gov registry entry for NCT02460731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 452-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (99% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Progressive Supranuclear Palsy appearing as the primary indexed condition, and to 1 intervention - of which Fresh Frozen Plasma is the first listed.

NCT02460731 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02460731 about?

NCT02460731 is a clinical study titled "Young Plasma Transfusions for Progressive Supranuclear Palsy". This is a phase 1, multi-center, open-label study of the safety, tolerability, pharmacodynamics, and preliminary efficacy of young (\<30 years of age) healthy male donor plasma transfusions in patients with PSP. Up to 10 subjects will receive once monthly 4-unit transfusions of young healthy male do...

What is the current status of trial NCT02460731?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2015-05. Estimated completion is 2019-12.

What conditions does trial NCT02460731 study?

This clinical trial studies the following conditions: Progressive Supranuclear Palsy.

What interventions are being tested in trial NCT02460731?

The interventions under investigation include: Fresh Frozen Plasma (BIOLOGICAL).

Who is sponsoring clinical trial NCT02460731?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02460731 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Progressive Supranuclear Palsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.